Common cancer risk and statins: A population-based case-control study in a Chinese population

Expert Opinion on Drug Safety

Volumn 12, Issue 1, 2013, Pages 19-27

  Leung, Henry Wc ^a   Chan, Agnes Lf ^a   Lo, Daniel ^b   Leung, John Hang ^c   Chen, Hsiao Ling ^d  

^a MIN SHENG GENERAL HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c ST JOHN'S UNIVERSITY   (United States)

^d CHI MEI MEDICAL CENTER   (Taiwan)

Author keywords

Cancer; Population based study; Statins

Indexed keywords

CARDIOVASCULAR AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER PREVENTION; CANCER RISK; CHARLSON COMORBIDITY INDEX; CHINESE; COLON CANCER; COLORECTAL CANCER; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG USE; FEMALE; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; LIVER CANCER; LONG TERM EXPOSURE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MENOPAUSE; NEOPLASM; PANCREAS CANCER; POPULATION BASED CASE CONTROL STUDY; PROSTATE CANCER; RECTUM CANCER; RISK REDUCTION; SKIN CANCER; STOMACH CANCER; TAIWAN; UTERUS CANCER;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; DRUG PRESCRIPTIONS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; STOMACH NEOPLASMS; TAIWAN; TIME FACTORS; UTERINE NEOPLASMS;

EID: 84871490146     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2013.744392     Document Type: Article

References (57)

1. Sewester CS, Dombek CE, Olin BR, et al. Drug facts and comparisons. 65th edition. Lippincott Williams & Wilkins; New York, NY: 2010
2. Chen BK. Three essays on physician prescribing behavior. Available from: http://www.slidefinder.net/t/three- essays-physician-prescribing-behavior/ 1984349 [Accessed 21 June 2011]
3. Pharmaceutical Industry. Available from: http://www.itis.org.tw/itisdata/ English/itispo-0453s702(97)-02-13-22.pdf [Accessed 21 June 2011]
4. Zamrini E, McGwin G, Roseman JM. Association between statin use and Alzheimer's disease. Neuroepidemiology 2004;23:94-8
5. Chan KA, Andrade SE, Boles M, et al. Inhibitors of hydroxymethylglutaryl- coenzymeA reductase and risk of fracture among older women. Lancet 2000;355:2185-8
6. Wang PS, Solomon DH, Mogun H, Avorn J. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 2000;283:3211-16
7. Meier CR, Schlienger RG, Kraenzlin ME, et al. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000;283:3205-10
8. Rejnmark L, Olsen ML, Johnsen SP, et al. Hip fracture risk in statin users-A population-based Danish case-control study. Osteoporos Int 2004;15:452-8
9. Jakobisiak M, Golab J. Potential antitumor effects of statins. Int J Oncol 2003;23:1055-69
10. Wong WW, Dimitroulakos J, Minden MD, et al. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002;16:508-19
11. Dimitroulakos J, Marhin WH, Tokunaga J, et al. Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinoma.Neoplasia 2002;4:337-46
12. Park HJ, Hong D, Iruela-Arispe L, et al. 3-hydroxy-3- methylglutarylcoenzyme a reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ Res 2002;91:143-50
13. Weis M, Heeschen C, Glassford AJ, et al. Statins have biphasic effects on angiogenesis. Circulation 2002;105:739-45
14. Alonso DF, Farina HG, Skilton G, et al. Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res Treat 1998;50:83-93
15. Kusama T, Mukai M, Iwasaki T, et al. 3-hydroxy-3-methylglutarylcoenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 2002;122:308-17
16. John S, Schneider MP, Delles C, et al. Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am Heart J 2005;149:473; e471-473.e410
17. Endres M. Statins: Potential new indications in inflammatory conditions. Atheroscler Suppl 2006;7:31-5
18. Setoguchi S, Glynn RJ, Avorn J, et al. Statins and the risk of lung, breast, and colorectal cancer in the elderly. irculation 2007;115(1):27-33
19. Boudreau DM, Yu O, Johnson J. Statin use and cancer risk: a comprehensive review. Expert Opin Drug Saf 2010;9(4):603-21
20. Boudreau DM, Yu O, Miglioretti DL, et al. Statin use and breast cancer risk in a large population-based setting. Cancer Epidemiol Biomarkers Prev 2007;16(3):416-21
21. Coogan PF, Rosenberg L, Strom BL. Statin use and the risk of 10 cancers. Epidemiology 2007;18(2):213-19
22. Friedman GD, Flick ED, Udaltsova N, et al. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361 859 recipients. Pharmacoepidemiol Drug Saf 2008;17(1):27-36
23. Jacobs EJ, Rodriguez C, Brady KA, et al. Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort. J Natl Cancer Inst 2006;98(1):69-72
24. Yang YX, Hennessy S, Propert K, et al. Chronic statin therapy and the risk of colorectal cancer. Pharmacoepidemiol Drug Saf 2008;17(9):869-76
25. Boudreau D, Yu O, Buist D, Miglioretti D. Statin use and prostate cancer risk in a large population based setting. Cancer Causes Control 2008;19(17):767-74
26. Agalliu I, Salinas CA, Hansten PD, et al. Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol 2008;168(3):250-60
27. Boudreau DM, Gardner JS, Malone KE, et al. The association between 3-hydroxy-3-methylglutaryl conenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: a case-control study. Cancer 2004;100(11):2308-16
28. Coogan PF, Smith J, Rosenberg L. Statin use and risk of colorectal cancer. J Natl Cancer Inst 2007;99(1):32-40
29. Hoffmeister M, Chang-Claude J, Brenner H. Individual and joint use of statins and low-dose aspirin and risk of colorectal cancer: a population-based case-control study. Int J Cancer 2007;121(6):1325-30
30. Flick ED, Habel LA, Chan KA, et al. Statin use and risk of colorectal cancer in a cohort of middle-Aged men in the US: a prospective cohort study. Drugs 2009;69(11):1445-57
31. Friis S, Poulsen AH, Johnsen SP, et al. Cancer risk among statin users: a population-based cohort study. Int J Cancer 2005;114(4):643-7
32. Haukka J, Sankila R, Klaukka T, et al. Incidence of cancer and statin usage-record linkage study. Int J Cancer 2010;126(1):279-84
33. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
34. Taiwan Cancer Registry. Available from: http://www.mc.ntu.edu.tw/CRS/ main. php?Page=N2
35. Application of ATC code. Available from: http://www.whocc.no/atc/ application-for-Atc-codes/[Accessed: 2011-3-628]
36. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
37. Chiu HF, Ho SC, Chang CC, et al. Statins are associated with a reduced risk of gastric cancer: a population-based case-control study. Am J Gastroenterol 2011;106(12):2098-103
38. Heiss G, Wallace R, Anderson GL, et al. Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin. JAMA 2008;299:1036-45
39. Kuoppala J, Lamminpa?a? A, Pukkala E. Statins and cancer: A systematic review and meta-Analysis. Eur J Cancer 2008;44(15):2122-32
40. Chiu HF, Ho SC, Chen CC, Yang CY. Statin use and the risk of liver cancer: a population-based case-control study. Am J Gastroenterol 2011;106(5):894-8
41. Kuo CC, Chiu HF, Lee IM, et al. Statin use and the risk of bladder cancer: a population-based case-control study. Expert Opin Drug Saf 2012;11(5):733-8
42. Chiu HF, Kuo CC, Kuo HW, et al. Statin use and the risk of kidney cancer: a population-based case-control study. Expert Opin Drug Saf 2012;11(4):543-9
43. Cheng MH, Chiu HF, Ho SC, et al. Statin use and the risk of colorectal cancer: a population-based case-control study. World J Gastroenterol 2011;17(47):5197-202
44. Cheng MH, Chiu HF, Ho SC, Yang CY. Statin use and the risk of female lung cancer: a population-based case-control study. Lung Cancer 2012;75(3):275-9
45. Chiu HF, Chang CC, Ho SC, et al. Statin use and the risk of pancreatic cancer: a population-based case-control study. Pancreas 2011;40(5):669-72
46. Chang CC, Ho SC, Chiu HF, Yang CY.Statins increase the risk of prostate cancer: a population-based case-control study. Prostate 2011;71(16):1818-24
47. Gauthaman K, Fong CY, Bongso A. Statins, stem cells, and cancer.J Cell Biochem 2009;106:975e83
48. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-Analysis of data from 90,056 participants in randomised trials of statins. Lancet 2005;366(9493):1267-78
49. Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer insights from large randomized statin trials. J Am Coll Cardiol 2007;50:409-18
50. Marelli C, Gunnarsson C, Ross S, et al. Statins and risk of cancer: a retrospective cohort analysis of 45,857 matched pairs from an electronic medical records database of 11 million adult Americans. J Am Coll Cardiol 2011;58(5):530-7
51. Rothwell PM, Price JF, Fowkes FG, et al. Short term effects of daily aspirin on cancer incidence mortality, and non-vasculardeath: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012;379:1602-12
52. Rothwell PM, Wilson M, Price JF, et al. Effect of daily aspirin on risk of cancer metastasis. A study of incident cancers during randomized controlled trials. Lancet 2012;379:1591-601
53. Chan AT, Cook NR. Are you ready to recommend aspirin for cancer prevention? Lancet 2012;379:1569-71
54. Sahra IB, Marchand-Brustel YL, Tanti JF, Bost F. Metformin in cancer therapy : a new perspective for an old diabetic drug? Mol Cancer Ther 2010;9(5):1092-9
55. Bonovas S, Filioussi K, Sitaras NM. Statin use and the risk of prostate cancer: a meta-Analysis of 6 randomized clinical trials and 13 observational studies. Int J Can 2008;123:899-904
56. Heart Protection Study Collaborative G. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360(9326):7-22
57. Vinogradova Y, Hippisley-Cox J, Coupland C, Logan RF. Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case-control study. Gastroenterology 2007;133(2):393-402